Dr. Liang Rui'an has been invited to attend the UK 2026 LifeArc Translational Science Summit

Dr. Ruian Liang Invited to Attend the UK 2026 LifeArc Translational Science Summit

China Antibody Limited (“China Antibody” or the “Company”, together with its subsidiaries, the “Group”, stock code: $SINOMAB BIO-B(3681.HK)) is pleased to announce that Dr. Ruian Liang, the Company’s Executive Director, Chairman and Chief Executive Officer, attended the 2026 LifeArc Translational Science Summit held recently in London, UK, as a special guest. As one of the globally influential events in the field of translational medicine, this summit gathered top scientists, clinicians, industry leaders, policymakers, and investment institutions from around the world. Dr. Liang delivered a keynote speech, systematically sharing China Antibody’s latest clinical progress in R&D strategies and core pipelines in the field of autoimmune diseases, and engaged in in-depth exchanges with international peers.

This summit was hosted by LifeArc, a well-known UK-based medical research charity. LifeArc has long been committed to promoting the translation of early-stage scientific research into clinical applications, with particularly profound influence in the fields of rare diseases and unmet medical needs. The summit focused on how translational research can accelerate the entire process from laboratory discovery to patient benefit by advancing novel therapeutic approaches, reshaping clinical practice, influencing health policies, and driving commercial innovation. Guests engaged in interdisciplinary dialogues around cutting-edge areas such as antibody drugs, gene therapy, and cell therapy, exploring how to overcome key bottlenecks in translational medicine and promote collaborative development among industry, academia, research, and medicine. Dr. Liang’s invitation signifies that China Antibody’s exploration in the field of innovative immunotherapy has garnered high-level attention from international authoritative institutions.

In the summit keynote report, Dr. Liang provided an in-depth analysis of the landscape and challenges in global autoimmune disease drug R&D, and elaborated on China Antibody’s differentiated innovation strategy centered on “First-in-Class and Best-in-Class.” He detailed the Company’s core product, SM17—a humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely acting on the key “alarmin” molecule IL-25 receptor upstream of the type II immune response, SM17 inhibits the inflammatory cascade at its source, demonstrating broad potential for treating various inflammatory and immune diseases such as atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Liang shared a series of substantial recent progress made by SM17: In the AD field, the Phase 1b clinical study of SM17 showed outstanding efficacy, with 91.7% of patients in the high-dose group achieving itch relief (NRS-4), 75% achieving skin lesion recovery (EASI 75), and 41.7% achieving complete or near-complete clearance of AD symptoms (IGA 0/1). The efficacy data was significantly superior to existing IL-4/IL-13 class monoclonal antibodies, with safety superior to JAK inhibitors. Based on this, the Phase II clinical trial of SM17 for moderate-to-severe AD completed the first patient dosing in China on March 31, 2026, with plans to enroll approximately 210 patients, expected to complete enrollment in the second half of 2026 and obtain topline data in the first half of 2027. In terms of dosing convenience, the Phase I bridging study of the subcutaneous formulation of SM17 achieved positive topline results on March 25, 2026. Data from 30 healthy subjects showed that subcutaneous injection had good safety and pharmacokinetic characteristics, with only one case of Grade 1 injection site rash that resolved spontaneously. The absolute bioavailability was robust, laying the foundation for the subsequent development of a more convenient subcutaneous dosing regimen. Furthermore, the indications of SM17 have been successfully expanded to IBD, with its Investigational New Drug (IND) application officially approved by China’s National Medical Products Administration on February 24, 2026, covering Crohn’s disease and ulcerative colitis. The related bridging study was completed in February 2026 and will directly advance to Phase II clinical development. Dr. Liang also introduced the innovative layout of the Company’s early-stage pipeline: The anti-CGC antibody (the world’s first humanized anti-γc antibody) has shown potential in treating autoimmune diseases such as alopecia areata and vitiligo, with plans to submit an IND application in the fourth quarter of 2026. The bispecific antibody targeting RANKL and sclerostin showed efficacy superior to existing marketed drugs in preclinical studies for bone-related indications, with plans to submit an IND application in the first half of 2027. Dr. Liang emphasized that by deeply cultivating innovative targets, China Antibody is gradually building a synergistic product matrix, aiming to provide safer, more effective, and more convenient breakthrough treatment options for patients worldwide.

This invitation to the LifeArc Translational Science Summit not only reflects the high recognition from international authoritative institutions of China Antibody’s innovative R&D capabilities and frontier exploration, but also provides an important platform for the Company to deepen global cooperation. Through in-depth exchanges with top global scientists, clinical researchers, and multinational pharmaceutical executives, China Antibody has further expanded its international academic network and potential collaboration channels, laying a solid foundation for future technology introduction, joint R&D, out-licensing, and commercialization. Dr. Liang stated that the Company will continue to focus on unmet clinical needs in the field of autoimmune diseases, accelerate the global multi-center clinical development of core pipelines such as SM17, actively explore the use of new technologies like artificial intelligence to empower new target discovery, and strengthen the translational capability from laboratory to clinic through strategic collaborations with institutions like the Sun Yat-sen University Hong Kong Advanced Research Institute. Looking ahead, China Antibody will seize the historical opportunity of the rapid growth of out-licensing in China’s biopharmaceutical sector, adhere to a differentiated global innovation path, actively seek diversified cooperation models with global partners, promote the faster global benefit of innovative achievements, and create long-term value for shareholders.

About China Antibody Limited

China Antibody Limited (stock code: $SINOMAB BIO-B(3681.HK)) is a pioneer in the research and development of first-in-class and potential best-in-class antibody drugs, focusing on autoimmune diseases and the resulting neurological disorders and other refractory wasting diseases, committed to addressing unmet medical needs. China Antibody is dedicated to developing therapeutic antibodies targeting novel targets and through innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies are suboptimal. Its rich R&D pipeline includes: SM17, which has demonstrated outstanding itch relief, skin clearance rate, and safety in AD treatment, while also having application potential in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Su Xili Monoclonal Antibody, besides clinically verified efficacy for rheumatoid arthritis (RA), is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer’s disease; another innovative anti-CGC (common gamma chain) monoclonal antibody is preparing to enter clinical studies for alopecia areata and vitiligo; China Antibody has also developed a bispecific antibody that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, China Antibody continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies.